Clinerion and the Precision Medicine-Hospital Information System Development Group of Korea University Medical Center Collaborate on Patient-Data-Driven Solutions for Precision Medicine
Clinerion and the Precision Medicine-Hospital Information System Development Group of Korea University Medical Center (P-HIS Development Group) sign a Memorandum of Understanding to support the development of the Korean national Precision Medicine Enterprise project with real-patient data solutions. Clinerion has signed a Memorandum of Understanding with the P-HIS Development Group of Korea University Medical Center (KUMC) to support the KUMC’s activities in developing a patient data platform in the Republic of Korea, in particular for precision medicine. Clinerion’s contribution will involve implementation and use of its Patient Network Explorer solution. The government of the Republic of Korea has created a National Key Project dedicated to precision medicine, involving both the Ministry of Science and IT and the Ministry of Health and Welfare. The KUMC leads this project, with twin pillars being the development of a universal common data model (as part of the Observational Health Data Sciences and Informatics (OHDSI) consortium) and a precision medicine cloud HIS platform (P-HIS). Both pillars will support the provision of a patient data platform which can be used for analysis for precision medicine. The Clinerion Patient Network Explorer (formerly PRS) enables the query of patient data from partner hospitals without compromising patient data privacy and without the data needing to leave the hospital IT infrastructure. The results of the queries are seen only as counts of patients matching inclusion/exclusion criteria; however, partner hospitals have a method of identifying matching anonymized patients for enrollment in clinical trials via Clinerion’s proprietary “Anonymized Identification” technology. “Clinerion’s established approach fits very well with the direction we have been pursuing,” says Professor Sang-Heon Lee, Head of Korea Precision Medicine Development Group and Professor at Korea University Medical Center. “We are very pleased with the reliability and scalability of their solution. As South Korea has very strict patient privacy regulations, we are also happy to see their in-built protections for privacy.” “The Republic of Korea offers a world-class stage for Clinerion which pushes the boundaries of technological possibility in secure patient data analytics,” says Ian Rentsch, CEO of Clinerion. “We are thrilled that KUMC offers us this chance to show the capabilities of Patient Network Explorer.” About Clinerion Clinerion enables early patient access to innovative treatments through real-patient data solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's Patient Network Explorer accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-driven protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion's solutions comply with international patient privacy and data security regulations. Clinerion website: www.clinerion.com Clinerion’s Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/Clineriontechnologysolution For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
